FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

0.5

Estimated average burden

hours per response:

	Check this box if no longer subject to
_	Section 16. Form 4 or Form 5
)	obligations may continue. See
	Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Tenenbaum Fabian</u>					2. Issuer Name and Ticker or Trading Symbol Bellerophon Therapeutics, Inc. [BLPH]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(1-10) (Fig.) (AFI-III)					Date of Earliest Transaction (Month/Day/Year)							Officer (below)	(give title	Other (below)	specify	
(Last) (First) (Middle) 184 LIBERTY CORNER ROAD					02/29/2016							CFO 8	& Chief Bu	isiness Offic	er	
SUITE 302					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable				
(Street)					4. If Amendment, Date of Original Fried (Month/Day/Tear)							Line)				
WARREN NJ 07059											2	X Form filed by One Reporting Person Form filed by More than One Reporting				
(City)	(S	tate)	(Zip)									Person	,		Ü	
. ,,	`	Ta		erivati	ve Se	curities	. Δr	auired D	isnosed o	of or Re	neficially	Owned				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction 2. Deemed 3. 4. Securities Acquired (A) or 5. Amount of 6. Ownership 7. Na													7. Nature of			
				Date (Month/Day/Ye		Execution Date, if any (Month/Day/Yea		Code (Instr.			tr. 3, 4 and 5	Beneficia Owned Fo	ully (D) or ollowing (I) (In	orm: Direct D) or Indirect) (Instr. 4)	Indirect Beneficial Ownership	
								Code V	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	on(s)		(Instr. 4)	
			Table II - Der (e.g					uired, Dis				Owned				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (action	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	1(5)		
Stock Option (right to buy)	\$2.3	02/29/2016		A		130,000		(1)	03/01/2026	Common Stock	130,000	\$0	130,000	D		

Explanation of Responses:

1. This option was granted on February 29, 2016. This option vests in four equal installments over a four-year period from the date of grant.

Remarks:

/s/ Fabian Tenenbaum

03/01/2016

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.